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Abstract 
Mucopolysaccharidosis  type  II  (MPS  II  or
Hunter syndrome) is a rare, inherited disorder
caused by deficiency of the lysosomal enzyme
iduronate-2-sulfatase. As a result of this defi-
ciency,  glycosaminoglycans  accumulate  in
lysosomes in many tissues, leading to progres-
sive  multisystemic  disease.  The  cardiopul-
monary and neurological problems associated
with MPS II have received considerable atten-
tion. Orthopedic manifestations are common
but not as well characterized. This study aimed
to characterize the prevalence and severity of
orthopedic  manifestations  of  MPS  II  and  to
determine the relationship of these signs and
symptoms with cardiovascular, pulmonary and
central nervous system involvement.
Orthopedic manifestations of MPS II were
studied  using  cross-sectional  data  from  the
Hunter Outcome Survey (HOS). The HOS is a
global, physician-led, multicenter observation-
al  database  that  collects  information  on  the
natural history of MPS II and the long-term
safety  and  effectiveness  of  enzyme  replace-
ment therapy. 
As  of  January  2009,  the  HOS  contained
baseline data on joint range of motion in 124
males with MPS II. In total, 79% of patients had
skeletal  manifestations  (median  onset,  3.5
years)  and  25%  had  abnormal  gait  (median
onset, 5.4 years). Joint range of motion was
restricted for all joints assessed (elbow, shoul-
der, hip, knee and ankle). Extension was the
most severely affected movement: the excep-
tion  to  this  was  the  shoulder.  Surgery  for
orthopedic problems was rare. The presence of
orthopedic manifestations was associated with
the  presence  of  central  nervous  system  and
pulmonary involvement, but not so clearly with
cardiovascular involvement.
Orthopedic interventions should be consid-
ered on an individual-patient basis. Although
some  orthopedic  manifestations  associated
with MPS II may be managed routinely, a good
knowledge of other concurrent organ system
involvement  is  essential.  A  multidisciplinary
approach is required. 
Introduction
Mucopolysaccharidosis  type  II  (MIM
309900) is a rare, X-linked disorder. It occurs
nearly exclusively in males, with an incidence
of  1  in  77,000  live  male  births.
1,2 Mutations
causing MPS II result in deficiency of the lyso-
somal enzyme iduronate-2-sulfatase (I2S; EC
3.1.6.13), which catalyses the degradation of
the glycosaminoglycans (GAGs) dermatan sul-
fate and heparan sulfate.
3 In the absence of
I2S, these GAGs accumulate in lysosomes with-
in the cells of many tissues, leading to progres-
sive multisystemic disease. 
Despite being caused by a specific enzyme
deficiency,  the  phenotype  of  MPS  II  varies
greatly from patient to patient so that there is
a  wide  spectrum  of  disease  severity.
Cardiopulmonary,  musculoskeletal,  gastroin-
testinal, dermatological and peripheral nervous
system manifestations of varying severity are
common  features  of  the  disease.
3,4 Patients
may also develop hepatosplenomegaly. Central
nervous system (CNS) involvement is, howev-
er, not experienced by all patients.
4,5 Patients
can be broadly classified as having one of two
forms of MPS II: a severe form or an attenuat-
ed  form.  In  the  severe  form  of  the  disease,
signs  and  symptoms  (including  neurological
impairment)  develop  in  early  childhood  and
progress  rapidly,  whereas  in  the  attenuated
form, signs and symptoms develop in adoles-
cence or early adulthood, and patients do not
experience significant cognitive impairment.
3
Both forms of the disease are associated with
reduced lifespan. Patients with the severe form
of MPS II are expected to survive until the sec-
ond decade of life. Those with the attenuated
form may have a longer lifespan and some have
been reported to survive into the fifth and sixth
decades of life.
3 Treatment of MPS II has tradi-
tionally been directed towards alleviation of the
signs  and  symptoms  of  the  disease.  Some
patients  have  also  undergone  hematopoietic
stem  cell  transplantation,  with  variable
degrees of success depending on the extent of
neurological involvement.
6-8 Recently, however,
a treatment that targets the underlying cause
of the disease has been developed, in the form
of  enzyme  replacement  therapy  (ERT)  with
idursulfase (Elaprase®, Shire Human Genetic
Therapies Inc., Cambridge, MA, USA). In ran-
domized clinical trials, ERT has been shown to
be successful in reducing liver and spleen vol-
umes,  improving  pulmonary  function  and
increasing  distance  walked  in  patients  with
MPS  II.
9,10 Treatment  was  well  tolerated  and
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most of the adverse events reported were con-
sistent  with  those  expected  in  an  untreated
population with MPS II.
Orthopedic  involvement  is  common  in
patients  with  MPS  II  and  leads  to  severe
restrictions in motion and impaired quality of
life.
3,5,11 Musculoskeletal manifestations report-
ed include arthropathy, contractures and joint
stiffness, claw hands, carpal tunnel syndrome,
short limb length, and deformities in the bones
of the spine, chest and limbs.
12-16 Spinal cord
compression  may  also  occur,
17,18 either  as  a
result of the spine deformities or due to soft
tissue involvement. In patients with the atten-
uated form of the disease, joint contractures
and skeletal alterations may be among the first
reported signs of MPS II.
4,19 Although joint con-
tractures  have  been  reported  to  improve  in
response to ERT, patients are likely to benefit
from  physical  therapy  and,  in  some  cases,
orthopedic surgery.
5
MPS II is one of a group of similar disorders
involving  GAG  accumulation  called  the
mucopolysaccharidoses  or  MPS  disorders.
Although there are few published studies on
changes to the cells of the musculoskeletal sys-
tem  in  MPS  II,
20,21 a  considerable  amount  is
known  about  the  cellular  and  physiological
mechanisms resulting in the musculoskeletal
manifestations  of  mucopolysaccharidoses  in
general.  GAGs  accumulate  in  nearly  all  cell
types leading to enlargement of the cells and
disruption  of  cellular  processes.  Progressive
disturbances  in  cell  physiology  finally  cause
cell death. The involvement of different tissues
depends on the degree and type of GAG accu-
mulation.
22 In MPS II, the GAGs stored within
the tissues and excreted in urine, are heparan
and dermatan sulfate. Storage is typically high
within cartilage, bone and connective tissues,
which may explain why the joints and bones
are  often  severely  affected  in  patients  with
MPS II.
3 Inflammation also has an important
role in the musculoskeletal manifestations of
the mucopolysaccharidoses.
23,24 In animal mod-
els of MPS disorders, GAG accumulation stim-
ulates  proliferation  of  synoviocytes  and
immune cells, and promotes infiltration of the
latter into various connective tissues.
25 In addi-
tion, articular chondrocytes have been found to
undergo  a  high  rate  of  apoptosis,  which
increases  with  age  and  is  associated  with
destructive  processes  in  the  joints.
23,26
Chondrocyte  death  is  compounded  by  the
mechanical  forces  placed  on  the  deformed
joints and spine, which leads to inflammatory
responses and matrix abnormalities, causing
further  destruction  of  cartilage  and  bone.
23
Osteoclasts seem to be essential mediators of
inflammatory bone erosion.
27 On one hand, the
rate  of  osteoclastogenesis  appears  to  be
increased in animal models of some MPS dis-
orders, on the other hand osteoclast morpholo-
gy and function appears to be abnormal. This
leads to fewer and thinner trabeculae, which
are  spaced  further  apart  than  normal.
25,27,28
Osteoblast activity was also decreased, as are
the number of osteoblast cells in the bone in
other animal models of MPS disorders.
25 MPS-
related osteopenia has been suggested to arise
from a defect in bone production within the
metaphysis and diaphysis rather than at the
growth  plate  cartilage.
28 A  combination  of
inflammation, activation of fibroblasts, distur-
bances in cartilage and bone, and increased
skin thickness are thought to be the cause of
contractures. Disturbances in the architecture
of the growth plate and a decreased ability of
bone cells to synthesize new bone on calcified
cartilage could account for short limb length
and bone deformities.
23,28 The underlying caus-
es of carpal tunnel syndrome are believed to be
thickening of the ligaments and synovia, as a
result  of  disruptions  to  the  functioning  of
macrophages and fibroblasts, and radio-ulnar
dissociation.
29
Patients  with  musculoskeletal  manifesta-
tions of MPS II should be referred to orthopedic
specialists, neurologists and physiotherapists;
however,  bearing  in  mind  the  multisystemic
nature  of  the  disease,  a  multidisciplinary
approach involving other specialist clinicians is
beneficial.  Furthermore,  as  new  treatments
become  available,  it  is  important  to  consider
how best to balance and optimize patient out-
comes.  Using  cross-sectional  data  from  the
Hunter Outcome Survey (HOS) (a global, multi-
center  observational  database  that  collects
information on the natural history of MPS II and
the long-term safety and effectiveness of ERT)
the aim of this manuscript is to characterize the
natural history of orthopedic manifestations in
patients with MPS II. This includes characteriz-
ing the prevalence and severity of orthopedic
manifestations, and determining the relation-
ship of these manifestations with cardiovascu-
lar,  pulmonary  and  neurological  signs  and
symptoms. It is hoped that the results will con-
tribute to a framework for clinical management
decisions in patients with MPS II. 
Materials and Methods
The  Hunter  Outcome  Survey  (HOS)  was
established in 2005. By gathering data from
patients with MPS II, the HOS aims to comple-
ment the information derived from clinical tri-
als  of  ERT  and  to  provide  the  basis  for  the
development  of  clinical  management  guide-
lines. Physicians and medical centers caring
for patients with MPS II are eligible to join the
HOS.  Before  enrolling  patients  in  the  data-
base,  each  participating  medical  center
received approval for taking part in the HOS
according  to  national  regulations;  typically
from their local Institutional Review Board or
Ethics Committee. 
Patients (males and females) with a con-
firmed  diagnosis  of  MPS  II  are  eligible  for
enrolment in the HOS, irrespective of whether
they are or are not receiving ERT. All enrolled
patients, or their parents or a legal representa-
tive, have provided written informed consent
for  participation  in  the  HOS.  Data  from
patients who had died before the initiation of
the HOS can also be entered into the database.
Only data collected during routine medical
examinations  are  entered  in  the  HOS.
Information reported includes vital signs, labo-
ratory test results, signs and symptoms of organ
involvement, and the results of functional analy-
ses such as audiometric tests, echocardiograms
and joint range of motion (JROM) tests. Data
entry and analysis in the HOS were conducted
as  previously  described.
30 A  computer-based
application is used to collect data and connects
via the internet to the database server using the
Secure Socket Layer protocol. This allows data
to  be  entered  remotely  at  hospital/physician
centers using locally secured connections. The
database is anonymous and confidential; data
that could be used to identify patients are acces-
sible only by the team treating the patient, on
their local computer. The survey is overseen by
national, regional and international scientific
advisory boards. Each advisory board consists
of  a  group  of  participating  physicians  who
were elected by all participating physicians. All
board members (who are experienced in the
management of MPS II) supervise the analysis
of data collected from national, regional, and
international cohorts of patients. Data collec-
tion  and  statistical  analysis  in  the  HOS  are
supported by Shire Human Genetic Therapies,
Inc. (Cambridge, MA, USA), a business unit of
Shire plc. 
Database population
HOS data for this analysis were collected on
or before 23 January 2009. At this time, 505
prospective patients (i.e. alive at HOS entry)
from 97 centers in 23 countries were enrolled
in the HOS. This analysis included all prospec-
tive  patients  (n=124;  all  male)  who  had  at
least  one  of  the  following  JROM  measure-
ments at baseline: shoulder flexion (range of
motion 0-180°), shoulder abduction (range of
motion 0-180°), hip flexion with the knee bent
(range  of  motion  0-125°),  hip  extension
(range of motion 0-40°), and hip internal rota-
tion  (range  of  motion  0-60°).
31 These  joints
were selected based on the clinical experience
of  the  authors  with  patients  with  MPS  II.
Information  that  was  available  from  the
patient group on other joints was also includ-
ed. For patients who had never received ERT,
baseline was defined as the latest measure-
ment recorded in HOS or the last visit record-
ed before death. In patients who had received
or were currently receiving ERT, baseline was
Articledefined  as  treatment  start  for  all  measure-
ments except for measurements of JROM. As
JROM  assessments  were  not  routinely  con-
ducted at the start of treatment, the measure-
ment taken closest to the date on which ERT
was started (either before the start or within
three months after the start of treatment) was
used as baseline. Data from patients for whom
treatment status was unclear were not includ-
ed. For one patient, the documentation of data
on hip and knee range of motion was inconsis-
tent with the methods specified in the HOS
and values could not be converted: these data
points were removed from the analysis. 
Descriptive statistics and data
analyses
The cumulative prevalence of signs and symp-
toms since birth was calculated at baseline for
the study population. The manifestations and
disease-related variables assessed are outlined
below. Variables assessed relating to orthopedic
involvement  included  joint  stiffness,  spine
deformities, gait, claw hand and type of orthope-
dic  surgical  procedures.  The  relationship
between an early onset of joint stiffness and the
development of scoliosis and kyphosis was also
assessed.  Early  onset  of  joint  stiffness  was
defined  as  onset  before  five  years  of  age.
Imaging data were available in the HOS for a
limited  number  of  patients  (n=39  for  spine;
n=30 for hip). Central nervous system (CNS)
manifestations included any one or combination
of the following: cognitive problems, behavioral
problems,  seizure  disorder,  hyperactivity,  fre-
quent  chewing  and  hydrocephalus.  Peripheral
nervous system (PNS) manifestations included
any one or combination of the following: carpal
tunnel syndrome, fine motor skill impairment
and abnormal reflexes. Cardiovascular involve-
ment was defined as any one or combination of
valve disease, heart murmur, bradycardia, tachy-
cardia, arrhythmia, cardiomyopathy, congestive
heart failure, hypertension, angina, infarction,
peripheral vascular disease, and/or an abnormal
heartbeat frequency range. Patients with bron-
chitis, bronchospasm, lower- and/or upper-air-
way infection, obstructive and/or restrictive air-
way  disease,  rales/crepitations  and/or  sleep
apnea, or those who required continuous posi-
tive airway pressure, mechanical ventilation or
bi-level  positive  airway  pressure,  or  who  had
oxygen  dependency,  were  considered  to  have
pulmonary involvement. For patients from whom
joint range of motion measurements (JROM)
for a particular joint were available on both sides
of  the  body,  the  correlation  between  JROM
measurements for the left and right sides of the
same joint was assessed. As there was a high
degree of correlation using Pearson’s correlation
coefficient between the left and right sides for
all five joints (shoulder flexion [n=108]: r=0.86,
P<0.001; shoulder abduction [n=117]: r=0.72,
P<0.001; hip flexion [n=104]: r=0.90, P<0.001;
hip  extension  [n=94]:  r=0.93,  P<0.001;  hip
internal  rotation  [n=78]:  r=0.83,  P<0.001),
mean values were used for further analyses in
patients for whom measurements were available
from both sides of the body. Actual values were
used when a measurement from only one side of
the  body  was  available.  JROM  measurements
were plotted relative to age at assessment, and
linear regression analyses were used to assess
the  relationship  between  these  two  variables.
Baseline measurements for distance walked in
the 6-minute walk test available in the database
were correlated with age. To assess what other
disease-related  manifestations  accompany
skeletal  involvement,  correlations  were  made
between  the  presence  of  different  orthopedic
manifestations  and  cardiovascular,  pulmonary
and CNS involvement.
Results
Baseline demographics 
The population analyzed included 124 out of
505 prospective patients with MPS II enrolled
in the HOS. Baseline characteristics of this
population are shown in Table 1. There was a
delay between the age at onset of symptoms
(median 2.0 years) and the age at diagnosis
(median 4.0 years), and between the age at
diagnosis and the age at which patients start-
ed ERT (median 10.2 years). The majority of
patients  (n=113)  were  receiving  ERT.
Baseline data were collected at a median age
of 10.3 years. 
Of the 124 patients included in the analysis,
27% had a family member with MPS II (67%
did not have a family member with MPS II, and
for 6% this information was missing). Patients
attended  centers  in  Europe  (70%),  Latin
America (20%) and North America (10%). 
Signs and symptoms in the patient
cohort
Table 2 shows the prevalence of CNS, PNS,
cardiovascular,  pulmonary  and  skeletal
involvement in the 124 patients with MPS II
included in this study. Data show that cardio-
vascular signs and symptoms were the most
prevalent  manifestations,  affecting  87.1%  of
patients.  Skeletal  manifestations  (excluding
Article
Table 1. Baseline characteristics of patients with mucopolysaccharidosis type II (MPS II)
included in the study (n=124)a.
Characteristic n
b
Median age (10
th-90
th percentile) at onset of symptoms, years  2.0(0.3-4.5) 105
Median age (10
th-90
th percentile) at diagnosis, years  4.0(1.5-8.0) 121
Receiving enzyme replacement therapy (ERT), n (%)
Yes 113 (91%)
No 11 (9%)
Started ERT before HOS entry, n (%) 74 (65%) 113
Median age (10
th-90
th percentile) at start of ERT, years  10.2 (5.1-24.9) 113
Median age (10
th-90
th percentile) at baselinec, years  10.3 (4.6-24.1) 124
Sex, n (%)
Male 124 (100%)
Other family member known to have MPS II, n (%) 117
Yes 34 (27%)
No 83 (67%)
Region, n (%)
North America 12 (10%)
Latin America 25 (20%)
Europe 87 (70%)
aTotal number of patients in the population studied; bNumber of patients for whom data were available on a given variable; cBaseline was
defined as the last measurement recorded in HOS for patients who had never received ERT and as treatment start for patients receiving ERT.
Table 2. Prevalence of central nervous system (CNS), peripheral nervous system (PNS),
cardiovascular, pulmonary and skeletal involvement in patients with MPS II (n=124). 
Sign or symptom N. patients
a Median age (10
th-90
th percentile) 
at onset (years)
CNS 58 (46.8%) 3.3 (0.1-11.5)
PNS 60 (48.4%) 5.7 (1.9-15.7)
Cardiovascular  108 (87.1%) 5.6 (1.7-14.2)
Pulmonary
b 86 (70.0%) 2.7 (0.1-13.4)
Skeletal
c 98 (79.0%) 3.5 (0.9-8.6)
aPrevalences are calculated from birth to last visit for untreated patients and from birth to treatment start for treated patients. bData on
chest and lung signs and symptoms were missing for one patient (n=123). cAny skeletal manifestations defined in Table 3A. 
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group with a median age at onset of 3.5 years.
Of  interest,  abnormal  gait  was  reported  in
25.0% of the patients, with a median age at
onset of 5.4 years (10
th-90
th percentile, 1.7-11.6
years). Pulmonary involvement was also very
common (affecting 70%) and was on average
the earliest manifestation to develop (median
age  at  onset,  2.7  years).  Almost  half  of  all
patients (46.8%) had CNS involvement, with
the first signs and symptoms being reported at
a median of 3.3 years of age. PNS involvement
also  affected  48.4%  of  the  patient  group,
although  the  onset  of  these  manifestations
was  slightly  later  than  CNS  manifestations
(median age at onset, 5.7 years). Carpal tunnel
syndrome affected 27.4% of patients and began
at  a  median  age  of  7.0  years  (10
th-90
th per-
centile, 3.6-17.3 years).
Figure 1 shows the typical skeletal manifes-
tations of MPS II. The prevalence of the indi-
vidual skeletal manifestations for which data
are  available  in  the  HOS  ranges  from  21.0-
75.0% (Table 3A). Median onset of these mani  -
festations  was  generally  between  four  and
seven  years  of  age.  Orthopedic  surgery  was
reported  in  some  patients  (Table  3B).  The
most  common  operation  was  carpal  tunnel
decompression  which  was  performed  in  24
patients. All other orthopedic surgeries (spinal
decompression, spine fusion, femoral osteoto-
my and trigger finger release surgery) were
carried  out  in  2.4%  or  fewer  of  the  124
patients.  Pelvic  osteotomy,  hip  replacement
and  arthroscopy  were  not  reported  to  have
been performed in any patient. 
For a small number of the total group of
patients,  detailed  data  on  spinal  and  hip
imaging were also available (Table 4). 
Article
Table 3A. Prevalence of skeletal involvement in patients with MPS II (n=124). 
Sign or symptom N. patients
a Median age (10
th-90
th percentile) 
at onset (years)
Kyphosis/scoliosis 42 (33.8%) 6.4 (0.6-15.9)
Claw hand 66 (53.2%) 4.2 (1.8-9.4)
Any joint stiffness 93 (75.0%) 4.0 (1.5-10.3)
Spine 26 (21.0%) 7.7 (1.6-15.4)
Shoulder 68 (54.8%) 4.6 (1.8-12.1)
Elbow 74 (59.7%) 5.1 (1.9-11.6)
Hand 80 (64.5%) 4.4 (1.9-10.2)
Hip 35 (28.2%) 5.6 (2.4-11.5)
Knee 53 (42.7%) 5.1 (2.3-11.6)
Ankle 42 (33.9%) 6.1 (2.6-11.6)
aPrevalences are calculated from birth to last visit for untreated patients and from birth to treatment start for treated patients. 
Table 3B. Prevalence of orthopedic surger-
ies in patients with MPS II (n=124). 
Location and type of surgery N.
patients
a
Spine
Spinal decompression  1 (<1%)
Spine fusion 1 (<1%)
Hip
Femoral osteotomy 3 (2.4%)
Pelvic osteotomy 0 
Hip replacement 0
Knee
Arthroscopy 0
Hand
Carpal tunnel decompression 24 (19.4%)
Trigger finger operation 2 (1.6%)
aPrevalences are calculated from birth to last visit for untreated
patients and from birth to treatment start for treated patients, and
based on the number of patients with available surgery data
(n=124).
Figure  1.  Typical  skeletal  manifesta-
tions of mucopolysaccharidosis type II
in an 18-year old patient. The patient
has  flexion  contraction  of  the  elbow,
knee and hip, as well as shortening of
the Achilles tendon and claw hands.
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Table 4. Prevalence of spinal and hip abnormalities identified based on available imaging
data (n=39 for spine; n=30 for hip).  
Location Abnormality N. patients (%) n
a
Any spinal abnormality
b 87.2 39
Cervical Vertebral deformity 68.8 32
Instability 3.1 32
Spinal cord compression 9.4 32
Thoracic Vertebral deformity 79.3 29
Spinal cord compression 3.4  29
Lumbar Vertebral deformity 93.8 32
Spinal cord compression 3.1 32
Any hip abnormalities
c 86.7 30
Hip Femoral head dysplasia 26.7 30
Acetabulum dysplasia 53.3 30
Coxa valga 16.7 30
Coxa vera 13.3 30
Femoral head necrosis 13.3 30
Degenerative changes 16.7 30
Other abnormality 23.3 30
aNumber of patients for whom data were available on that variable. 
bPrevalences are based on the number of patients with available data for
each section of the spine (cervical n=32; thoracic n=29; lumbar n=32). Data on the spine were based on X-ray (n=34), magnetic resonance
imaging (n=11), and computed tomography scan (n=1) (more than one imaging method was used in some patients). 
cData on the hip were
based on X-rays (n=30). [page 60] [Orthopedic Reviews 2010; 2:e16]
A spinal abnormality was present in 34 of the
39  patients  (87.2%)  for  whom  imaging  data
were available. The most common abnormali-
ties were cervical, thoracic and lumber vertebral
deformities  (affecting  68.8-93.8%).  Cervical
spinal  cord  compression  was  reported  in  3
patients.  Cervical  instability,  thoracic  spinal
cord compression and lumbar spinal cord com-
pression were each reported in one patient. A
hip abnormality was present in 26 of the 30
patients  (86.7%)  for  whom  hip  images  were
included in the HOS (all X-rays). The most com-
mon  abnormality  was  acetabulum  dysplasia
(affecting 53.3%), followed by femoral head dys-
plasia (affecting 26.7%) (Figure 2).
JROM and the 6-minute walk test 
JROM measurements are shown in Table 5.
There was evidence of restriction in the range
of motion for all of the joints assessed. For the
majority of joints that were studied (the elbow,
wrist, hip, knee and ankle), the movement that
was  most  severely  affected  was  extension.
Other movements of these joints were general-
ly near-normal or less severely affected. For the
shoulder,  the  most  severely  affected  joint
motions were abduction and flexion.
32,33
Joint restriction increased with age. Simple
linear regression analysis showed a negative
relationship between age and JROM for each
of the major joints studied. This relationship
was  significant  for  shoulder  abduction,  hip
flexion with the knee bent, hip extension and
hip internal rotation (Table 6). The relation-
ship between hip flexion and age is illustrated
in Figure 3.
The median distance walked in the 6-minute
walk test was 362 meters (range 37-569 meters;
n=84).  Distance  walked  was  not  correlated
with age at assessment (r=0.17, P=0.122).
Relationship between orthopedic
manifestations of MPS II and other
disease-related manifestations
Skeletal  manifestations  were  usually
accompanied by other serious disease-related
manifestations. In general, there was a clear
association between the presence of individ-
ual orthopedic manifestations and the pres-
ence of CNS and pulmonary involvement, but
not so clearly with the presence of cardiovas-
cular  involvement  (Table  7).  Patients  with
orthopedic  manifestations  were  generally
more likely to have CNS and pulmonary mani-
festations than those without orthopedic man-
ifestations. However, patients with orthopedic
manifestations were only very slightly more
likely  to  have  cardiovascular  manifestations
than  patients  who  did  not  have  orthopedic
manifestations.
Joint stiffness 
Patients with joint stiffness were more like-
ly to have CNS and pulmonary manifestations
than  those  without  joint  stiffness:  55.9%  of
patients with and 19.4% of those without joint
stiffness had CNS signs/symptoms, and 79.6%
of patients with and 40.0% of patients without
joint stiffness had pulmonary manifestations.
Overall, 89.7% of patients with CNS manifesta-
tions  and  86.0%  of  patients  with  pulmonary
Article
Table 5. Joint range of motion measurements in patients with MPS II (n=124). 
Joint and movement n
a Median (10
th-90
th Normal 
percentile) JROM (°) JROM (°)
b
Predominantly affected joint movements 
Shoulder flexion  108 119 (90-153) 150-180
Shoulder abduction  117 98 (75-130) 180
Hip flexion, knee bent  105 110 (85-130) 100-120
Hip extension  96 0 (–25 to 20) 20-30
Hip internal rotation  78 25 (10-40) 40-45
Other joint movements
Wrist flexion  109 55 (30-75) 60-80
Wrist extension  116 30 (8-64) 60-70
Shoulder internal rotation  83 57 (36-85) 70-90
Shoulder external rotation  85 61 (30-85) 90
Shoulder extension  81 54 (35-73) 50-60
Elbow flexion  107 135 (110-150) 140-150
Elbow extension  106 -27 (-51 to 10) 0-10
Hip abduction  91 33 (20-46) 40
Hip adduction  44 20 (13-30) 20
Hip external rotation  79 32 (23-61) 45-50
Knee flexion  105 130 (105-145) 150
Knee extension  101 -10 (-25 to 5) 0-10
Ankle dorsal extension  85 4 (-15 to 20) 20
Ankle plantar flexion  45 41 (20-50) 40-50
aNumber of patients for whom data were available on that variable. bNormal ranges of joint motion are defined according to a combination of
the criteria developed by the American Medical Association (AMA) and the American Association of Orthopedic Surgeons (AAOS).
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Figure 2. X-ray of an 18-year old patient
with mucopolysaccharidosis type II show-
ing femoral head necrosis and the typical
features of dysostosis multiplex.
Table 6. Simple linear regression parameters between joint range of motion and age for
each of the joints that are known to be predominantly affected in patients with MPS II. 
Joint All values Pa
N Parameter estimate (SE)
Shoulder flexion 108 -0.36 (0.27) 0.181
Shoulder abduction 117 -0.77 (0.23) <0.001
Hip flexion, knee bent 105 -0.83b (0.22) <0.001
Hip extension 96 -0.46c (0.21) 0.030
Hip internal rotation 78 -0.59 (0.14) <0.001
SE, standard error. aP value based on t-test for the hypothesis: parameter estimate = 0. bParameter estimate = -0.87 (SE, 0.15) when exclud-
ing outliers. cParameter estimate = -0.33 (SE, 0.18) when excluding the outlier.
Figure  3.  The  relationship  between  hip
flexion with knee bent and age. 
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manifestations  also  had  joint  stiffness.
Cardiovascular manifestations were common
both in patients with and without joint stiff-
ness (90.3% and 77.4%, respectively). 
Having  early  joint  stiffness  and/or  spine
deformity (onset before five years of age) was
associated with the presence of CNS involve-
ment in patients who were eight years or older
at latest HOS visit (P=0.001). In total, 67.3% of
patients with early-onset joint stiffness/spine
deformity  had  developed  CNS  involvement.
Among patients who did not have early-onset
joint  stiffness/spine  deformity,  34.0%  devel-
oped  CNS  manifestations  (data  reported  on
Table 7). 
Kyphosis 
The  presence  of  kyphosis  was  associated
with CNS manifestations in 72.4% of patients;
however,  CNS  manifestations  were  recorded
for only 38.9% of patients who did not have
kyphosis. The majority of patients with kypho-
sis  (86.2%)  had  pulmonary  manifestations,
whereas 64.9% of those without kyphosis had
pulmonary involvement. It is noteworthy that
all patients with kyphosis had cardiovascular
involvement, compared with 83.2% of patients
without kyphosis (data reported Table 7). 
Discussion
Musculoskeletal manifestations are known
to be common in patients with MPS II, and are
associated with complex changes in bone, car-
tilage and soft tissues. This was the first study
to investigate the prevalence and severity of
musculoskeletal  manifestations  and  orthope-
dic surgical procedures in such a large group
of  patients  with  this  rare  disorder.  Detailed
investigations  were  based  on  data  obtained
during routine clinical practice by physicians
treating patients with MPS II and collected in
the HOS database. Despite the obvious limita-
tions of survey-based data, the results obtained
from this analysis provide insight into clinical
experience with the orthopedic/skeletal mani-
festations of MPS II.
Skeletal  manifestations  were  found  to  be
prevalent  in  patients  with  MPS  II,  affecting
about 80% of the group of 124 patients in the
HOS for whom data were available. Skeletal
deformities  were  normally  seen  first  in  the
hand and wrist, with 53.2% of patients having
clawed hands at a median age of 4.2 years.
Claw hands are typically associated with short-
ening of the ligaments and broadened bones,
often leading to carpal tunnel syndrome and a
significant  reduction  in  fine  motor  control.
Restriction of movement of the wrist was doc-
umented  in  terms  of  flexion  and  extension,
probably  leading  to  a  reduction  in  hand
strength. The hand was also the area in which
joint  stiffness  was  most  commonly  reported
(64.5%). Joint stiffness was also common in
the  elbow  (59.7%),  shoulder  (54.8%),  knee
(42.7%)  and  ankle  (33.9%).  Joint  stiffness
appeared in the hand at a median age of 4.4
years and in the shoulder at a median age of
4.6  years.  Joint  stiffness  generally  became
apparent in the elbow and knee when children
were slightly older (median onset, 5.1 years).
The  next  two  joints  in  which  stiffness  was
reported to have developed were the hip (medi-
an onset 5.6, years) and ankle (median onset,
6.1 years). Spinal deformities (kyphosis or sco-
liosis) and spine stiffness generally developed
later in the disease, with a median age at onset
of 6.4 and 7.7 years, respectively. It is notewor-
thy  that  there  was  an  association  between
kyphosis and CNS involvement, and scoliosis
and CNS involvement. All patients with kypho-
sis or scoliosis also had cardiovascular mani-
festations.  Although  kyphosis  and  scoliosis
together affected only 33.8% of patients stud-
ied, kyphosis in particular may be indicative of
a severe disease course. Early onset of joint
stiffness and/or spinal deformities (kyphosis
or  scoliosis)  (before  five  years  of  age)  was
associated with the presence of CNS involve-
ment in patients who were eight years or older
at latest HOS visit; however, it was not possible
to  determine  whether  the  development  of
skeletal manifestations preceded the onset of
CNS involvement.
Contractures of nearly all of the main joints
(elbow,  wrist,  shoulder,  hip  and  knee)  were
consistent  features  of  MPS  II  with  onset  in
early childhood. Of note, the movement that
was  most  severely  restricted  was  extension.
Joint contractures often prevent patients with
MPS  II  from  standing  erect  and  may  limit
mobility, as shown by the reported abnormal
gait in 25.0% of the patients in the present
study, as well as the limited distance walked in
the 6-minute walk test. It is clinically logical to
speculate that the severely limited extension
of the hip (by up to 55°), in combination with
the extension deficits in the knee (by up to
45°) and foot (by up to 25°), contributed to the
characteristic abnormal gait of patients with
MPS  II.  Regarding  the  severe  limitation  in
shoulder mobility found in the current analy-
sis, particularly in terms of flexion (by up to
90°) and abduction (by up to 105°), we hypoth-
esize that this was the result of damage to the
soft  tissues  surrounding  the  shoulder  joint
owing  to  GAG  storage.  In  combination  with
deficits in the flexion contraction of the elbow
by up to 51°, this would result in a significant
impairment in the motion of the arm. Overall,
our analysis showed that assessment of flexion
and abduction of the shoulder, and extension
of the elbow, wrist, knee and ankle, appear to
be useful for documenting the disease burden
in terms of joint restriction. 
Radiographic examination of patients with
MPS disorders has generally revealed the typi-
cal features of dysostosis multiplex, with abnor-
mal thickness of all bones, irregular epiphysial
ossification of many joints and anterior break-
ing of vertebral bodies of the entire spine.
22,34 In
the  current  study,  imaging  data  showed  evi-
dence  of  some  characteristics  of  dysostosis
multiplex. Hip deformity in terms of acetabu-
lum dysplasia was apparent in more than half
of those patients for whom hip images were
Article
Table 7. Relationship between selected orthopedic manifestations and CNS, pulmonary and cardiovascular manifestations (Fisher’s
exact test). 
Orthopedic manifestation CNS manifestations Pulmonary manifestation Cardiovascular manifestation
Yes No P value Yes No P value Yes No P value
n (%) n (%) n (%) n (%) n (%) n (%)
Joint stiffness Yes 52 (55.9) 41 (44.1) < 0.001 74 (79.6) 19 (20.4) < 0.001 84 (90.3) 9 (9.7) 0.117
No 6 (19.4) 25 (80.6) 12 (40.0) 18 (60.0) 24 (77.4) 7 (22.6)
Scoliosis Yes 12 (60.0) 8 (40.0) 0.227 19 (95.0) 1 (5.0) 0.007 20 (100) 0 (0) 0.072
No 46 (44.2) 58 (55.8) 67 (65.0) 36 (35.0) 88 (84.6) 16 (15.4)
Kyphosis Yes  21 (72.4) 8 (27.6) 0.003 25 (86.2) 4 (13.8) 0.037 29 (100) 0 (0) 0.022
No 37 (38.9) 58 (61.1) 61 (64.9) 33 (35.1) 79 (83.2) 16 (16.8)
Claw hand Yes 41 (62.1) 25 (37.9) < 0.001 54 (81.8) 12 (18.2) 0.003 61 (92.4) 5 (7.6) 0.067
No 17 (29.3) 41 (70.7) 32 (56.1) 25 (43.9) 47 (81.0) 11 (19.0) available, and was associated with degenera-
tive changes in the femoral heads in some, but
not all, cases. Acetabulum dysplasia is probably
the result of the disturbances in the architec-
ture of the growth plate and the decreased abil-
ity of bone cells to synthesize new bone on cal-
cified cartilage.
23,25,28 Hip dysplasia is predictive
of osteoarthritis and poor mobility
35,36 and, in
otherwise healthy patients, surgery is indicated
to preserve long-term mobility. In the current
investigation,  3  patients  with  MPS  II  were
reported to have undergone femoral osteotomy.
Limited experience with other MPS disorders
suggests that patients may also benefit from
innominate osteotomy.
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Descriptions of spine deformities in MPS II
are relatively rare in the literature;
8,13 however,
it  is  clear  that  the  spine  is  affected  in  the
majority of patients with MPS II. Radiographic
data in this study suggested a high prevalence
of spinal abnormalities (87.2%), with the most
common malformation being vertebral defor-
mity; however, it is important to bear in mind
that these data may be biased as little imaging
data were available in the HOS. Spinal cord
compression  caused  by  dural  thickening
and/or by instability of the atlanto-axial joint
has been reported in patients with MPS disor-
ders.
18,38,39 In  the  current  study,  unusual  and
extensive changes in the anatomy of the spine
led  to  spinal  cord  compression  or  cervical
instability in up to 12.5% of the patients for
whom imaging data were available in the HOS.
One patient showed cervical, thoracic and lum-
bar  spinal  cord  compression,  2  patients
showed cervical spinal cord compression and
one patient showed cervical instability. 
Patients with MPS II should be screened for
clinical and radiological signs of spinal cord
compression. Signs of spinal cord compression
may include abnormal gait, muscle weakness,
dysesthesia  and  bladder  dysfunction.
Instability  of  the  atlanto-axial  joint  can  be
identified  by  flexion-extension  radiographs.
Spinal cord compression, secondary to dural
thickening,  must  be  confirmed  by  magnetic
resonance imaging.
18 In this cohort, only one
patient was documented as having undergone
spinal decompression and one had undergone
surgery for spine fusion at baseline. In the lit-
erature, experience of spinal cord decompres-
sion in patients with MPS II is also limited.
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However, because compression of the spinal
cord is often associated with irreversible neu-
rological dysfunction, decompression surgery
should be considered in patients with MPS II
as soon as possible after signs of compression
are confirmed. 
Carpal tunnel syndrome is the most com-
mon entrapment neuropathy in adults, but it is
rarely seen in children.
12 However, carpal tun-
nel  syndrome  was  commonly  seen  in  young
patients  with  MPS  II  in  the  current  study
(affecting  27.4%  of  patients  with  a  median
onset at 7.0 years). This is consistent with a
review of published literature that found MPS
disorders to be the major cause of carpal tun-
nel syndrome during childhood.
12Carpal tunnel
syndrome may result in contracture of distal
interphalangeal joints, as well as dysesthesia,
loss of feeling in the first three fingers, and
paresis  of  the  thenar  muscles.
40 Deco  -
mpression  surgery  is  recommended  in
patients for whom either loss of hand function
or  large  decreases  in  nerve  conduction  are
demonstrated, and is reported to result in rapid
and  sustained  improvement  of  function.
41 In
this cohort, 19.4% of the patients underwent
the procedure, although based on the propor-
tion of patients in whom carpal tunnel syn-
drome  was  reported  (27.4%),  more  patients
would probably have benefited from this sur-
gery. In summary, patients with MPS II may
benefit from regular assessment to detect the
development of carpal tunnel syndrome. 
When considering any surgical procedure in
a patient with MPS II it is important to keep
other  organ  system  manifestations  in  mind.
Results of the current analysis showed that the
majority of patients with MPS II, both with and
without skeletal manifestations, have cardio-
vascular  involvement.  Orthopedic/skeletal
manifestations  were,  however,  frequently
accompanied  by  both  CNS  and  pulmonary
involvement. Among patients with joint stiff-
ness, for example, 90% also had cardiovascular
involvement, 80% also had pulmonary involve-
ment, and 57% also had CNS manifestations.
This shows that patients with skeletal mani-
festations generally have clear multisystemic
involvement.  It  is,  therefore,  important  that
concurrent disease manifestations are identi-
fied and taken into account before undertaking
any surgical procedures. In addition, anatomi-
cal changes including short neck, atlanto-axial
instability, lung impairment and cardiovascu-
lar problems may complicate general anesthe-
sia in patients with MPS II.
14,42,43 Intubation and
extubation, in particular, are usually difficult
in patients with MPS II.
42 Despite these consid-
erations, orthopedic surgery clearly has a role
in the management of MPS II. 
Patients  may  also  benefit  from  physical
therapy although there are no published stud-
ies as of yet providing evidence of benefit of
physical therapy in MPS II. Physical therapy is
designed  to  preserve  and  improve  physical
function and offers a non-surgical approach
to the management of joint involvement in
MPS  II.  Techniques  that  may  be  beneficial
include physiotherapy, and alternative thera-
pies like hippotherapy, dolphin therapy and
dance movement therapy, as well as occupa-
tional therapy. Before initiating physical ther-
apy, the first step should be to rule out the
possibility that the musculoskeletal manifes-
tations  are  of  neurological  origin.  Subse  -
quently,  it  is  possible  to  design  a  program
directed  at  addressing  the  specific  problem
areas for the individual. This program may
involve mobilization, strength and endurance
training, enhancement of fine motor skills for
the hands, and gait training for lower limb
joints. It is especially important to document
progress by performing baseline assessments
and conducting periodic evaluations. In addi-
tion  to  physical  therapy,  the  mobility  of
patients may be improved by the use of ortho-
pedic  aids  and  devices.  Although  physical
therapy and the use of orthopedic devices are
intended  to  improve  musculoskeletal  and
sometimes  cardiopulmonary  function,  by
improving  patient  mobility  they  can  also
address some of the psychological aspects of
the  condition  by  increasing  independence
and  reducing  anxiety.  In  recent  years,
improvements  in  patient  identification,  care
and management mean that patients with MPS
II are living longer.
44 With the introduction of
ERT it is clear that we can expect additional
benefits in terms of improvements in visceral
manifestations and increased mobility, as evi-
dent from increased distances walked on the 6-
minute walk test.
9 Although there is some indi-
cation that joint contractures may be improved
by ERT, both ERT and bone marrow transplan-
tation are likely to have only a limited impact
on bone and joint disease based on the results
of studies in animal models.
45,46This may be due
partly to some of the irreversible changes in
bone structure known to be induced by GAG
accumulation.
26 Thus, physical therapy and cor-
rective surgery should be considered, although
the long-term outcome for patients with MPS II
remains  unclear  because  ERT  is  unlikely  to
influence the cognitive aspects of the condi-
tion.  Owing  to  the  heterogeneous  nature  of
MPS II, it is clear that no single management
strategy can be used for all patients. Instead,
individual  management  programs  should  be
developed based on the disease progression in
each patient, with input from the multidiscipli-
nary  specialists  caring  for  the  patient.
Pediatricians,  neurologists,  neurosurgeons,
cardiologists, anesthesiologists and pulmonolo-
gists may all play a role in orthopedic decisions. 
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